AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
| AbbVie (NYSE: ABBV) | Delayed: 286.74 +1.10 (0.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $285.64 | 52 Week High | $68.12 | |||
| Open | $287.05 | 52 Week Low | $50.71 | |||
| Day High | $289.59 | P/E | 62.20 | |||
| Day Low | $285.18 | EPS | $4.61 | |||
| Volume | 4,515,919 | |||||
